Kym Hoger

Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.

Benjamin S. Hughes, C. Broder, D. Dimitrov, 2020, The Lancet. Infectious diseases.

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

D. Purcell, K. Subbarao, Thi H. O. Nguyen, 2021, The Lancet Infectious Diseases.

Molecular clamp stabilised Spike protein for protection against SARS-CoV-2

Benjamin S. Hughes, K. Subbarao, T. Munro, 2020 .

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

Benjamin S. Hughes, K. Subbarao, T. Munro, 2021, Clinical & translational immunology.